Recent Publications

CONCLUSIONS: By integrating these innovative features, with specialized survival analyses on single-cell cluster markers, co-expression modules, regulatory networks, and ligand-receptor pairs, Survival Genie 2 represents a novel tool for expanding the translational impact of cancer research, enabling the precise identification of biomarkers and therapeutic targets. Survival Genie 2 is available at https://bhasinlab.bmi.emory.edu/SurvivalGenie2/home.

Multiple myeloma (MM) is a plasma cell malignancy shaped by dynamic interactions between MM cells and non-malignant cells in the immune microenvironment. To spatially profile the influence of cellular context on MM and immune cell expression, we developed a multimodal framework integrating 10x Genomics Visium HD, 10x Genomics Xenium, and clinically annotated single-cell RNA (scRNA-seq) sequencing datasets. Visium HD enabled unbiased, whole transcriptome, spatial discovery at 16 µm resolution,...

BACKGROUND: The role of adipokines in childhood glycemia is poorly understood. We investigate the longitudinal association between adipokines and glycemia in a cohort of children in Mexico City.

Atherosclerosis develops unevenly across the vascular tree, yet the molecular basis for this regional susceptibility remains poorly defined. The left internal mammary artery (LIMA), the most durable conduit for coronary artery bypass (CABG) surgery, is uniquely resistant to atherosclerosis in humans; however, it has never been isolated or studied in mouse models, limiting mechanistic insight into atheroprotective pathways. Here, we establish the first method to identify and isolate the murine...

Multiple myeloma (MM) remains incurable despite advances in treatment options. Although tumor subtypes and specific DNA abnormalities are linked to worse prognosis, the impact of immune dysfunction on disease emergence and/or treatment sensitivity remains unclear. We developed an Immune Atlas of MM by generating profiles of 1,397,272 single cells from the bone marrow (BM) of 337 newly diagnosed participants and characterized immune and hematopoietic cell populations. Cytogenetic risk-based...

CONCLUSIONS: WP1066 is safe, has minimal toxicity, and induces anti-tumor immune responses in pediatric brain tumor patients. Phase II investigation of WP1066 at the MFD in this patient population is warranted.